Skip to content
Back to ROIV

Roivant Sciences Ltd.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
127
Purchases
0
Sales
127
Purchase value
$0.00
Sale value
$636.17M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

QVT Financial LPDirector by Deputization
4
Filed Nov 18, 2026Period of report Nov 16, 20260001193125-26-467296
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 17, 2026
Common SharesF1F275,716$38.24$2.90M13,499,093IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleNov 17, 2026
Common SharesF1F2525,507$38.24$20.10M0IndirectHeld by QVT P&E Roiv Hldgs Ltd
SaleNov 17, 2026
Common SharesF1F2798$38.24$30.52K5,805,461IndirectHeld by QVT Deferred Compensation Holdings Ltd.
SaleNov 16, 2026
Common SharesF1F279,461$39.17$3.11M13,609,705IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleNov 16, 2026
Common SharesF1F2550,280$39.17$21.55M1,042,200IndirectHeld by QVT P&E Roiv Hldgs Ltd
SaleNov 16, 2026
Common SharesF1F218,927$38.99$737.96K13,590,778IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleNov 16, 2026
Common SharesF1F2131,073$38.99$5.11M911,127IndirectHeld by QVT P&E Roiv Hldgs Ltd
Filing footnotes · 3
  1. F1Aggregately, following the transactions described above, QVT Financial LP ("QVT"), a Delaware limited partnership, may be deemed to be the beneficial owner of 19,304,554 Common Shares, consisting of the Common Shares owned by QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC"). QVT Financial GP LLC, a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT.
  2. F2QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
  3. F3On November 17, 2026, each of QVT P&E, QVT DCH and QVT FIC made an in-kind distribution on a pro rata basis, for no consideration.
Open on SEC EDGAR
Richard PulikCFO
4
Filed Nov 12, 2026Period of report Nov 10, 20260001635088-26-000139
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 11, 2026
Common SharesF245,195$41.47$1.87M351,851Direct
SaleNov 11, 2026
Common SharesF382,170$42.03$3.45M269,681Direct
SaleNov 11, 2026
Common SharesF447,635$41.89$2.00M222,046Direct
SaleNov 10, 2026
Common SharesF1125,000$41.20$5.15M269,681Direct
Filing footnotes · 5
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.16 to $41.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.88 to $41.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  3. F3The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.94 to $42.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  4. F4The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.79 to $42.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  5. F5Reflects an award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4Rule 10b5-1 plan disclosed
Filed Nov 12, 2026Period of report Nov 10, 20260001635088-26-000137
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 10, 2026
Common SharesF1158,194$40.44$6.40M840,960Direct
SaleNov 10, 2026
Common SharesF229,749$41.00$1.22M811,211Direct
Filing footnotes · 2
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 to $40.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.93 to $41.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026.
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4Rule 10b5-1 plan disclosed
Filed Nov 5, 2026Period of report Nov 3, 20260001635088-26-000123
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 3, 2026
Common SharesF1200,000$36.31$7.26M999,154Direct
Filing footnotes · 1
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.75 to $36.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026.
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4Rule 10b5-1 plan disclosed
Filed Oct 30, 2026Period of report Oct 28, 20260001635088-26-000120
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 28, 2026
Common SharesF1200,000$36.59$7.32M1,199,154Direct
Filing footnotes · 1
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.18 to $36.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026.
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4Rule 10b5-1 plan disclosed
Filed Oct 22, 2026Period of report Oct 20, 20260001635088-26-000116
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 20, 2026
Common SharesF1185,856$35.09$6.52M1,413,298Direct
SaleOct 20, 2026
Common SharesF214,144$35.42$500.98K1,399,154Direct
Filing footnotes · 2
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.38 to $35.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.39 to $35.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026.
Open on SEC EDGAR
Epperly Melissa BDirector
4Rule 10b5-1 plan disclosed
Filed Oct 5, 2026Period of report Oct 1, 20260001807359-26-000018
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 1, 2026
Common SharesF116,850$36.08$607.95K15,854Direct
SaleOct 1, 2026
Common SharesF2900$36.57$32.91K14,954Direct
Filing footnotes · 3
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $36.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
  3. F3Reflects an award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4Rule 10b5-1 plan disclosed
Filed Oct 2, 2026Period of report Sep 30, 20260001635088-26-000108
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 30, 2026
Common SharesF1200,000$36.62$7.32M1,599,154Direct
Filing footnotes · 2
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
  2. F2Reflects an award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Epperly Melissa BDirector
4Rule 10b5-1 plan disclosed
Filed Sep 17, 2026Period of report Sep 15, 20260001807359-26-000014
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 15, 2026
Common SharesF14,338$39.65$172.00K10,500Direct
SaleSep 15, 2026
Common SharesF2600$40.38$24.23K9,900Direct
Filing footnotes · 2
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.25 to $40.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.25 to $40.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
Open on SEC EDGAR
Meghan FitzgeraldDirector
4Rule 10b5-1 plan disclosed
Filed Sep 17, 2026Period of report Sep 15, 20260001349297-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 15, 2026
Common SharesF14,712$39.68$186.97K36,508Direct
SaleSep 15, 2026
Common SharesF2400$40.45$16.18K36,108Direct
Filing footnotes · 2
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.26 to $40.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.28 to $40.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
Open on SEC EDGAR
Meghan FitzgeraldDirector
4Rule 10b5-1 plan disclosed
Filed Sep 10, 2026Period of report Sep 8, 20260001140361-26-036246
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 8, 2026
Common SharesF120,000$39.90$798.00K42,963Direct
Filing footnotes · 2
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.90 to $40.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.
  2. F2Reflects an award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4Rule 10b5-1 plan disclosed
Filed Sep 1, 2026Period of report Aug 28, 20260001140361-26-035375
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 28, 2026
Common SharesF1166,182$35.63$5.92M1,632,972Direct
SaleAug 28, 2026
Common SharesF233,818$36.44$1.23M1,599,154Direct
Filing footnotes · 3
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.17 to $36.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.17 to $36.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
  3. F3Reflects an award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Mayukh SukhatmeDirector · President & CIO
4
Filed Aug 21, 2026Period of report Aug 19, 20260001140361-26-034066
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 21, 2026
Common SharesF3144,756$36.48$5.28M18,630,739Direct
SaleAug 20, 2026
Common SharesF217,519$37.30$653.46K18,630,739Direct
SaleAug 19, 2026
Common SharesF1172,899$37.17$6.43M18,630,739Direct
Filing footnotes · 4
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.80 to $37.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.20 to $37.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  3. F3The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $37.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  4. F4Award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Mayukh SukhatmeDirector · President & CIO
4
Filed Aug 18, 2026Period of report Aug 14, 20260001140361-26-033637
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 18, 2026
Common SharesF3105,141$36.59$3.85M18,630,739Direct
SaleAug 18, 2026
Common SharesF431,801$37.18$1.18M18,630,739Direct
SaleAug 17, 2026
Common SharesF2284,707$36.25$10.32M18,630,739Direct
SaleAug 14, 2026
Common SharesF1243,177$36.23$8.81M18,630,739Direct
Filing footnotes · 5
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $36.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $36.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  3. F3The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $37.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  4. F4The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.10 to $37.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  5. F5Award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4Rule 10b5-1 plan disclosed
Filed Jul 29, 2026Period of report Jul 27, 20260001140361-26-030107
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 27, 2026
Common SharesF1200,000$34.95$6.99M1,613,063Direct
Filing footnotes · 2
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.62 to $35.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2Reflects an award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Meghan FitzgeraldDirector
4Rule 10b5-1 plan disclosed
Filed Jul 2, 2026Period of report Jun 30, 20260001349297-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 30, 2026
Common Shares10,000$34.90$349.00K42,963Direct
Filing footnotes · 1
  1. F1Award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Keith S ManchesterDirector
4
Filed Jun 30, 2026Period of report Jun 26, 20260001193125-26-291172
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 30, 2026
Common SharesF112,380$35.28$436.77K13,689,166IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleJun 30, 2026
Common Shares200,000$35.45$7.09M1,748,403Direct
SaleJun 29, 2026
Common SharesF1200,000$34.44$6.89M14,301,546IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleJun 29, 2026
Common SharesF1600,000$34.59$20.75M13,701,546IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleJun 26, 2026
Common SharesF1300,783$33.92$10.20M14,826,546IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleJun 26, 2026
Common SharesF1325,000$34.07$11.07M14,501,546IndirectHeld by QVT Financial Investment Cayman Ltd.
Filing footnotes · 1
  1. F1The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
Daniel Allen GoldDirector
4
Filed Jun 30, 2026Period of report Jun 26, 20260001193125-26-291163
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 30, 2026
Common SharesF112,380$35.28$436.77K13,689,166IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleJun 29, 2026
Common SharesF1200,000$34.44$6.89M14,301,546IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleJun 29, 2026
Common SharesF1600,000$34.59$20.75M13,701,546IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleJun 26, 2026
Common SharesF1300,783$33.92$10.20M14,826,546IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleJun 26, 2026
Common SharesF1325,000$34.07$11.07M14,501,546IndirectHeld by QVT Financial Investment Cayman Ltd.
Filing footnotes · 1
  1. F1The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. ("QVT FIC"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
QVT Financial LPDirector by Deputization
4
Filed Jun 30, 2026Period of report Jun 26, 20260001193125-26-291139
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 30, 2026
Common SharesF1F212,380$35.28$436.77K13,689,166IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleJun 29, 2026
Common SharesF1F2200,000$34.44$6.89M14,301,546IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleJun 29, 2026
Common SharesF1F2600,000$34.59$20.75M13,701,546IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleJun 26, 2026
Common SharesF1F2300,783$33.92$10.20M14,826,546IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleJun 26, 2026
Common SharesF1F2325,000$34.07$11.07M14,501,546IndirectHeld by QVT Financial Investment Cayman Ltd.
Filing footnotes · 2
  1. F1Aggregately, following the transactions described above, QVT Financial LP ("QVT"), a Delaware limited partnership, may be deemed to be the beneficial owner of 23,723,074 Common Shares, consisting of the Common Shares owned by QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT FIC. QVT Financial GP LLC ("QVT Financial GP"), a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT.
  2. F2QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E, QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
Epperly Melissa BDirector
4Rule 10b5-1 plan disclosed
Filed Jul 1, 2026Period of report Jun 29, 20260001807359-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 29, 2026
Common SharesF115,002$34.32$514.87K19,222Direct
SaleJun 29, 2026
Common SharesF22,748$34.71$95.38K16,474Direct
Filing footnotes · 3
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.65 to $34.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  3. F3Reflects an award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Mayukh SukhatmeDirector · President & CIO
4
Filed Jun 29, 2026Period of report Jun 25, 20260001635088-26-000073
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 26, 2026
Common SharesF2500,000$34.08$17.04M18,677,617Direct
SaleJun 25, 2026
Common SharesF1500,000$34.13$17.07M18,677,617Direct
Filing footnotes · 3
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.87 to $34.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.75 to $34.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  3. F3Award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4Rule 10b5-1 plan disclosed
Filed Jun 26, 2026Period of report Jun 24, 20260001635088-26-000071
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 24, 2026
Common SharesF1153,766$33.05$5.08M1,659,297Direct
SaleJun 24, 2026
Common SharesF246,234$33.51$1.55M1,613,063Direct
Filing footnotes · 3
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.23 to $33.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.23 to $33.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  3. F3Reflects an award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4Rule 10b5-1 plan disclosed
Filed May 22, 2026Period of report May 20, 20260001635088-26-000065
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 22, 2026
Common SharesF2200,000$30.27$6.05M1,613,063Direct
Filing footnotes · 3
  1. F1Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
  2. F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  3. F3Reflects an award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4Rule 10b5-1 plan disclosed
Filed Apr 22, 2026Period of report Apr 20, 20260001635088-26-000044
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 20, 2026
Common SharesF1200,000$29.59$5.92M1,647,546Direct
Filing footnotes · 2
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.33 to $29.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2Reflects an award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Matthew GlineDirector · CEO
4
Filed Apr 20, 2026Period of report Apr 16, 20260001635088-26-000038
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 16, 2026
Common SharesF1289,774$29.16$8.45M16,736,116Direct
Filing footnotes · 1
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.98 to $29.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
Open on SEC EDGAR
Jennifer HumesChief Accounting Officer
4
Filed Apr 10, 2026Period of report Apr 8, 20260001140361-26-014301
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 8, 2026
Common SharesF113,538$28.37$384.07K84,191Direct
Filing footnotes · 1
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.36 to $28.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
Open on SEC EDGAR
Meghan FitzgeraldDirector
4
Filed Mar 30, 2026Period of report Mar 26, 20260001140361-26-012063
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 26, 2026
Common SharesF170,000$27.45$1.92M42,963Direct
Filing footnotes · 2
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.32 to $27.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2Award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4Rule 10b5-1 plan disclosed
Filed Mar 19, 2026Period of report Mar 17, 20260001635088-26-000026
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 17, 2026
Common SharesF1200,000$28.24$5.65M1,647,546Direct
Filing footnotes · 2
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.04 to $28.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
Open on SEC EDGAR
Epperly Melissa BDirector
4
Filed Mar 18, 2026Period of report Mar 16, 20260001807359-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 16, 2026
Common SharesF141,861$28.68$1.20M15,804Direct
Filing footnotes · 1
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $28.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
Open on SEC EDGAR
Frank TortiPresident and Vant Chair
4Rule 10b5-1 plan disclosed
Filed Feb 23, 2026Period of report Feb 19, 20260001635088-26-000019
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 23, 2026
Common SharesF1F4587,390$27.51$16.16M13,736,547Direct
SaleFeb 20, 2026
Common SharesF1F31,012,610$27.15$27.49M13,736,547Direct
SaleFeb 19, 2026
Common SharesF1F21,400,000$27.42$38.39M13,736,547Direct
Filing footnotes · 5
  1. F1The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2These Common Shares were sold in multiple transactions at prices ranging from $27.00 to $27.64, inclusive.
  3. F3These Common Shares were sold in multiple transactions at prices ranging from $26.70 to $27.45, inclusive.
  4. F4These Common Shares were sold in multiple transactions at prices ranging from $27.14 to $27.80, inclusive.
  5. F5Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date (except as otherwise provided in the award documentation).
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4Rule 10b5-1 plan disclosed
Filed Feb 18, 2026Period of report Feb 13, 20260001635088-26-000017
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 13, 2026
Common SharesF1200,000$26.49$5.30M1,654,597Direct
Filing footnotes · 2
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.35 to $26.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
Open on SEC EDGAR
Keith S ManchesterDirector
4
Filed Feb 13, 2026Period of report Feb 11, 20260001193125-26-052130
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 13, 2026
Common SharesF1150,784$26.49$3.99M15,352,329IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleFeb 13, 2026
Common SharesF1225,000$26.50$5.96M15,127,329IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleFeb 12, 2026
Common SharesF1150,000$26.72$4.01M15,778,113IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleFeb 12, 2026
Common SharesF1275,000$26.76$7.36M15,503,113IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleFeb 11, 2026
Common SharesF1425,000$26.67$11.33M15,928,113IndirectHeld by QVT Financial Investment Cayman Ltd.
Filing footnotes · 1
  1. F1The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
Daniel Allen GoldDirector
4
Filed Feb 13, 2026Period of report Feb 11, 20260001193125-26-052128
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 13, 2026
Common SharesF1150,784$26.49$3.99M15,352,329IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleFeb 13, 2026
Common SharesF1225,000$26.50$5.96M15,127,329IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleFeb 12, 2026
Common SharesF1150,000$26.72$4.01M15,778,113IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleFeb 12, 2026
Common SharesF1275,000$26.76$7.36M15,503,113IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleFeb 11, 2026
Common SharesF1425,000$26.67$11.33M15,928,113IndirectHeld by QVT Financial Investment Cayman Ltd.
Filing footnotes · 1
  1. F1The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. ("QVT FIC"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
QVT Financial LPDirector by Deputization
4
Filed Feb 13, 2026Period of report Feb 11, 20260001193125-26-052106
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 13, 2026
Common SharesF1F2150,784$26.49$3.99M15,352,329IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleFeb 13, 2026
Common SharesF1F2225,000$26.50$5.96M15,127,329IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleFeb 12, 2026
Common SharesF1F2150,000$26.72$4.01M15,778,113IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleFeb 12, 2026
Common SharesF1F2275,000$26.76$7.36M15,503,113IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleFeb 11, 2026
Common SharesF1F2425,000$26.67$11.33M15,928,113IndirectHeld by QVT Financial Investment Cayman Ltd.
Filing footnotes · 2
  1. F1Aggregately, following the transactions described above, QVT Financial LP ("QVT"), a Delaware limited partnership, may be deemed to be the beneficial owner of 25,161,237 Common Shares, consisting of the Common Shares owned by QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT FIC. QVT Financial GP LLC ("QVT Financial GP"), a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT.
  2. F2QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E, QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
Mayukh SukhatmeDirector · President & CIO
4
Filed Feb 11, 2026Period of report Feb 9, 20260001635088-26-000015
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 9, 2026
Common SharesF1F2339,441$26.47$8.99M19,148,664Direct
Filing footnotes · 4
  1. F1All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2These Common Shares were sold in multiple transactions at prices ranging from $25.92 to $26.78, inclusive.
  3. F3Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.
  4. F4Award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4Rule 10b5-1 plan disclosed
Filed Jan 14, 2026Period of report Jan 12, 20260001140361-26-001239
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 12, 2026
Common SharesF1200,000$21.92$4.38M1,654,597Direct
Filing footnotes · 2
  1. F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.59 to $22.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
Open on SEC EDGAR
Mayukh SukhatmeDirector · President & CIO
4
Filed Dec 31, 2025Period of report Dec 29, 20250001140361-25-047122
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 31, 2025
Common SharesF1F31,018,995$21.71$22.12M20,267,429Direct
SaleDec 29, 2025
Common SharesF1F2311,873$21.74$6.78M19,273,032Direct
Filing footnotes · 5
  1. F1All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.90, inclusive.
  3. F3These Common Shares were sold in multiple transactions at prices ranging from $21.70 to $21.74, inclusive.
  4. F4Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.
  5. F5Award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4
Filed Dec 29, 2025Period of report Dec 23, 20250001140361-25-046786
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 24, 2025
Common SharesF1F2F475,000$22.53$1.69M1,654,597Direct
SaleDec 23, 2025
Common SharesF1F2F3200,000$22.45$4.49M1,611,749Direct
Filing footnotes · 5
  1. F1Represents an exercise and hold transaction, with a sale of Common Shares only to cover applicable withholding taxes and the exercise price of the stock options exercised.
  2. F2The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  3. F3These Common Shares were sold in multiple transactions at prices ranging from $22.25 to $22.64, inclusive.
  4. F4These Common Shares were sold in multiple transactions at prices ranging from $22.50 to $22.63, inclusive.
  5. F5Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
Open on SEC EDGAR
Richard PulikCFO
4
Filed Dec 29, 2025Period of report Dec 23, 20250001140361-25-046787
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 23, 2025
Common SharesF1F2260,000$22.45$5.84M386,144Direct
SaleDec 23, 2025
Common SharesF1F3146,731$22.39$3.29M239,413Direct
Filing footnotes · 4
  1. F1The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2These Common Shares were sold in multiple transactions at prices ranging from $22.37 to $22.51, inclusive.
  3. F3These Common Shares were sold in multiple transactions at prices ranging from $22.28 to $22.54, inclusive.
  4. F4Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
Open on SEC EDGAR
Mayukh SukhatmeDirector · President & CIO
4
Filed Dec 19, 2025Period of report Dec 17, 20250001140361-25-046247
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 17, 2025
Common SharesF126,831$23.09$619.53K18,869,229Direct
Filing footnotes · 3
  1. F1All options exercised by the reporting person would have expired in March 2026 if not exercised. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
  2. F2Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.
  3. F3Award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Daniel Allen GoldDirector
4
Filed Dec 18, 2025Period of report Dec 16, 20250001193125-25-325359
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 17, 2025
Common SharesF1432,718$23.05$9.97M16,697,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleDec 17, 2025
Common SharesF1155,076$23.02$3.57M16,542,651IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleDec 17, 2025
Common SharesF1189,538$23.17$4.39M16,353,113IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleDec 16, 2025
Common SharesF1275,000$22.93$6.31M17,772,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleDec 16, 2025
Common SharesF1642,282$23.08$14.82M17,130,445IndirectHeld by QVT Financial Investment Cayman Ltd.
Filing footnotes · 1
  1. F1The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. ("QVT FIC"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
Keith S ManchesterDirector
4
Filed Dec 18, 2025Period of report Dec 16, 20250001193125-25-325355
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 17, 2025
Common SharesF1432,718$23.05$9.97M16,697,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleDec 17, 2025
Common SharesF1155,076$23.02$3.57M16,542,651IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleDec 17, 2025
Common SharesF1189,538$23.17$4.39M16,353,113IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleDec 16, 2025
Common SharesF1275,000$22.93$6.31M17,772,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleDec 16, 2025
Common SharesF1642,282$23.08$14.82M17,130,445IndirectHeld by QVT Financial Investment Cayman Ltd.
Filing footnotes · 1
  1. F1The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
QVT Financial LPDirector by Deputization
4
Filed Dec 18, 2025Period of report Dec 16, 20250001193125-25-325343
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 17, 2025
Common SharesF1F2432,718$23.05$9.97M16,697,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleDec 17, 2025
Common SharesF1F2155,076$23.02$3.57M16,542,651IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleDec 17, 2025
Common SharesF1F2189,538$23.17$4.39M16,353,113IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleDec 16, 2025
Common SharesF1F2275,000$22.93$6.31M17,772,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleDec 16, 2025
Common SharesF1F2642,282$23.08$14.82M17,130,445IndirectHeld by QVT Financial Investment Cayman Ltd.
Filing footnotes · 2
  1. F1Aggregately, following the transactions described above, QVT Financial LP ("QVT"), a Delaware limited partnership, may be deemed to be the beneficial owner of 26,387,021 Common Shares, consisting of the Common Shares owned by QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC"). QVT Financial GP LLC, a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT.
  2. F2QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E, QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
Matthew GlineDirector · CEO
4
Filed Dec 17, 2025Period of report Dec 15, 20250001140361-25-045906
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 15, 2025
Common SharesF1230,357$21.68$4.99M17,290,820Direct
SaleDec 15, 2025
Common SharesF1566,116$21.68$12.27M18,084,676Direct
SaleDec 15, 2025
Common SharesF1943,527$21.68$20.46M18,616,406Direct
Filing footnotes · 3
  1. F1All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934.
  2. F2Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.
  3. F3Award of stock options to purchase Common Shares that is fully vested.
Open on SEC EDGAR
Ramaswamy Vivek10% owner
4
Filed Dec 15, 2025Period of report Dec 11, 20250001635075-25-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 15, 2025
Common SharesF4353,745$22.05$7.80M34,132,463Direct
SaleDec 12, 2025
Common SharesF31,975,858$21.96$43.39M36,350,621Direct
SaleDec 11, 2025
Common SharesF1774,142$21.64$16.75M34,749,305Direct
Filing footnotes · 7
  1. F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.35 to $22.05, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.
  2. F2Represents the "net settlement" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options.
  3. F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.65 to $22.13, inclusive.
  4. F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.88 to $22.49, inclusive.
  5. F5Represents the quantity of shares held indirectly only.
  6. F6Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
  7. F7All options exercised by the reporting person would have expired in March 2026 if not exercised.
Open on SEC EDGAR
Eric VenkerPresident & Immunovant CEO
4Rule 10b5-1 plan disclosed
Filed Dec 11, 2025Period of report Dec 9, 20250001140361-25-045279
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 9, 2025
Common SharesF1200,000$20.85$4.17M1,497,908Direct
Filing footnotes · 2
  1. F1The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
  2. F2Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
Open on SEC EDGAR
Keith S ManchesterDirector
4
Filed Nov 21, 2025Period of report Nov 19, 20250001193125-25-291734
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 19, 2025
Common SharesF1850,000$20.25$17.21M18,497,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleNov 19, 2025
Common SharesF1150,000$20.20$3.03M18,347,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleNov 19, 2025
Common SharesF1125,000$20.16$2.52M18,222,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleNov 19, 2025
Common SharesF1175,000$20.24$3.54M18,047,727IndirectHeld by QVT Financial Investment Cayman Ltd.
Filing footnotes · 1
  1. F1The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
Daniel Allen GoldDirector
4
Filed Nov 21, 2025Period of report Nov 19, 20250001193125-25-291731
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 19, 2025
Common SharesF1850,000$20.25$17.21M18,497,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleNov 19, 2025
Common SharesF1150,000$20.20$3.03M18,347,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleNov 19, 2025
Common SharesF1125,000$20.16$2.52M18,222,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleNov 19, 2025
Common SharesF1175,000$20.24$3.54M18,047,727IndirectHeld by QVT Financial Investment Cayman Ltd.
Filing footnotes · 1
  1. F1The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. ("QVT FIC"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR
QVT Financial LPDirector by Deputization
4
Filed Nov 21, 2025Period of report Nov 19, 20250001193125-25-291727
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 19, 2025
Common SharesF1F2850,000$20.25$17.21M18,497,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleNov 19, 2025
Common SharesF1F2150,000$20.20$3.03M18,347,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleNov 19, 2025
Common SharesF1F2125,000$20.16$2.52M18,222,727IndirectHeld by QVT Financial Investment Cayman Ltd.
SaleNov 19, 2025
Common SharesF1F2175,000$20.24$3.54M18,047,727IndirectHeld by QVT Financial Investment Cayman Ltd.
Filing footnotes · 2
  1. F1Aggregately, following the transactions described above, QVT Financial LP ("QVT"), a Delaware limited partnership, may be deemed to be the beneficial owner of 28,081,635 Common Shares, consisting of the Common Shares owned by QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC"). QVT Financial GP LLC ("QVT Financial GP"), a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT.
  2. F2QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E, QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.